Loading...
Although azathioprine and mycophenolate mofetil are the two most common steroid-sparing agents used for myasthenia gravis, limited high-quality evidence is available comparing them. To compare their efficacy, investigators conducted a propensity-matched, observational, multicenter cohort study of adult patients (median age, 67) from academic centers in the U.S. and Canada who were started on azathioprine (31 patients) or mycophenolate mofetil (47 patients) and had not previously received corticosteroids, other immunosuppressants, or rescue treatments. Most patients had generalized myasthenia gravis. The median follow-up was 25 months for mycophenolate mofetil and 20 months for azathioprine. There were two coprimary outcomes: patient-reporte…